272 related articles for article (PubMed ID: 23833193)
1. Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission.
Farrand L; Byun S; Kim JY; Im-Aram A; Lee J; Lim S; Lee KW; Suh JY; Lee HJ; Tsang BK
J Biol Chem; 2013 Aug; 288(33):23740-50. PubMed ID: 23833193
[TBL] [Abstract][Full Text] [Related]
2. The diarylheptanoid hirsutenone sensitizes chemoresistant ovarian cancer cells to cisplatin via modulation of apoptosis-inducing factor and X-linked inhibitor of apoptosis.
Farrand L; Kim JY; Byun S; Im-aram A; Lee J; Suh JY; Lee KW; Lee HJ; Tsang BK
J Biol Chem; 2014 Jan; 289(3):1723-31. PubMed ID: 24247248
[TBL] [Abstract][Full Text] [Related]
3. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.
Yuan Z; Cao K; Lin C; Li L; Liu HY; Zhao XY; Liu L; Deng HX; Li J; Nie CL; Wei YQ
Mol Med; 2011; 17(11-12):1262-74. PubMed ID: 21863213
[TBL] [Abstract][Full Text] [Related]
4. Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking.
Woo MG; Xue K; Liu J; McBride H; Tsang BK
J Biol Chem; 2012 Feb; 287(6):3963-75. PubMed ID: 22117079
[TBL] [Abstract][Full Text] [Related]
5. p53 is required for cisplatin-induced processing of the mitochondrial fusion protein L-Opa1 that is mediated by the mitochondrial metallopeptidase Oma1 in gynecologic cancers.
Kong B; Wang Q; Fung E; Xue K; Tsang BK
J Biol Chem; 2014 Sep; 289(39):27134-27145. PubMed ID: 25112877
[TBL] [Abstract][Full Text] [Related]
6. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells.
Fraser M; Leung BM; Yan X; Dan HC; Cheng JQ; Tsang BK
Cancer Res; 2003 Nov; 63(21):7081-8. PubMed ID: 14612499
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells.
Han Y; Kim B; Cho U; Park IS; Kim SI; Dhanasekaran DN; Tsang BK; Song YS
Oncogene; 2019 Nov; 38(45):7089-7105. PubMed ID: 31409904
[TBL] [Abstract][Full Text] [Related]
8. Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101.
Hu W; Wang F; Tang J; Liu X; Yuan Z; Nie C; Wei Y
J Biol Chem; 2012 Jan; 287(1):68-80. PubMed ID: 22052903
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation.
Mansouri A; Zhang Q; Ridgway LD; Tian L; Claret FX
Oncol Res; 2003; 13(6-10):399-404. PubMed ID: 12725530
[TBL] [Abstract][Full Text] [Related]
10. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
Yang X; Fraser M; Moll UM; Basak A; Tsang BK
Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
[TBL] [Abstract][Full Text] [Related]
11. HOXB9 Overexpression Confers Chemoresistance to Ovarian Cancer Cells by Inducing ERCC-1, MRP-2, and XIAP.
Suh DH; Park WH; Kim M; Kim K; No JH; Kim YB
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674764
[TBL] [Abstract][Full Text] [Related]
12. The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.
Ui T; Morishima K; Saito S; Sakuma Y; Fujii H; Hosoya Y; Ishikawa S; Aburatani H; Fukayama M; Niki T; Yasuda Y
Oncol Rep; 2014 Feb; 31(2):619-24. PubMed ID: 24317439
[TBL] [Abstract][Full Text] [Related]
13. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
Sasaki H; Sheng Y; Kotsuji F; Tsang BK
Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
[TBL] [Abstract][Full Text] [Related]
15. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.
Washington MN; Suh G; Orozco AF; Sutton MN; Yang H; Wang Y; Mao W; Millward S; Ornelas A; Atkinson N; Liao W; Bast RC; Lu Z
Cell Death Dis; 2015 Aug; 6(8):e1836. PubMed ID: 26247722
[TBL] [Abstract][Full Text] [Related]
16. Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer.
Wang Y; Mao H; Hao Q; Wang Y; Yang Y; Shen L; Huang S; Liu P
Regul Pept; 2012 Oct; 178(1-3):36-42. PubMed ID: 22759793
[TBL] [Abstract][Full Text] [Related]
17. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
Wu AY; Gu LY; Cang W; Cheng MX; Wang WJ; Di W; Huang L; Qiu LH
J Exp Clin Cancer Res; 2019 Apr; 38(1):176. PubMed ID: 31023317
[TBL] [Abstract][Full Text] [Related]
18. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
Yan X; Fraser M; Qiu Q; Tsang BK
Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
[TBL] [Abstract][Full Text] [Related]
19. P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism.
Al-Bahlani S; Fraser M; Wong AY; Sayan BS; Bergeron R; Melino G; Tsang BK
Oncogene; 2011 Oct; 30(41):4219-30. PubMed ID: 21516125
[TBL] [Abstract][Full Text] [Related]
20. Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells.
Karaca B; Atmaca H; Bozkurt E; Kisim A; Uzunoglu S; Karabulut B; Sezgin C; Sanli UA; Uslu R
Mol Biol Rep; 2013 Jun; 40(6):3925-33. PubMed ID: 23269627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]